LON:SLNSilence Therapeutics Share Price, Forecast & News

Silence Therapeutics' stock was trading at GBX 470 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, SLN stock has decreased by 7.0% and is now trading at GBX 437. View which stocks have been most impacted by Coronavirus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Silence Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Silence Therapeutics.

Silence Therapeutics plc (LON:SLN) released its quarterly earnings data on Tuesday, September, 11th. The company reported ($12.40) earnings per share for the quarter. View Silence Therapeutics' earnings history.

1 analysts have issued 1 year price targets for Silence Therapeutics' shares. Their forecasts range from GBX 605 to GBX 605. On average, they anticipate Silence Therapeutics' stock price to reach GBX 605 in the next year. This suggests a possible upside of 38.4% from the stock's current price. View analysts' price targets for Silence Therapeutics.

News coverage about SLN stock has trended neutral on Sunday, InfoTrie reports. The research group rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Silence Therapeutics earned a media sentiment score of 0.4 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news about Silence Therapeutics.

Some companies that are related to Silence Therapeutics include NGM Biopharmaceuticals (NGM), Concordia International (CXR), Clinuvel Pharmaceuticals (CUV), BELLUS Health (BLU), Trillium Therapeutics (TRIL), PureTech Health (PRTC), Aptose Biosciences (APS), Oxford BioMedica (OXB), CEL-SCI (CVM), Cel-Sci (CVM), Paradigm Biopharmaceuticals (PAR), SIGA Technologies (SIGA), Biotest (BIO), Neptune Wellness Solutions (NEPT) and TELIX Pharmaceutical (TLX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Silence Therapeutics investors own include Arch Therapeutics (ARTH), QuickLogic (QUIK), Asiamet Resources (ARS), ArcBest (ARCB), American Renal Associates (ARA), Apergy (APY), ANCHIANO THERAP/S (ANCN), Aileron Therapeutics (ALRN), Alkermes (ALKS) and Alfa Financial Software (ALFA).

Silence Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "SLN."

Shares of SLN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

One share of SLN stock can currently be purchased for approximately GBX 437.

Silence Therapeutics has a market capitalization of £361.95 million and generates £244,000.00 in revenue each year.

The official website for Silence Therapeutics is www.silence-therapeutics.com.

Silence Therapeutics' mailing address is 72 Hammersmith Road, LONDON, W14 8TH, United Kingdom. The company can be reached via phone at +44-20-34576900.